| 2.37 0.01 (0.42%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.27 | 1-year : | 5.68 |
| Resists | First : | 3.65 | Second : | 4.86 |
| Pivot price | 2.07 |
|||
| Supports | First : | 1.7 | Second : | 1.41 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.13 |
| MA(100) : | 4.46 |
MA(250) : | 8.72 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 77 |
D(3) : | 78.2 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 19.35 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATOS ] has closed below upper band by 19.9%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.38 - 2.39 | 2.39 - 2.4 |
| Low: | 2.2 - 2.21 | 2.21 - 2.22 |
| Close: | 2.35 - 2.37 | 2.37 - 2.39 |
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Wed, 08 Jul 2026
Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Mon, 06 Jul 2026
ATOS - Atossa Therapeutics Inc Short Interest - Finviz
Mon, 29 Jun 2026
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Mon, 29 Jun 2026
Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Index - marketscreener.com
Thu, 25 Jun 2026
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic? - simplywall.st
Fri, 12 Jun 2026
Cancer-drug developer Atossa raises $4.5M, eyes $12M more - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 16.2 (%) |
| Shares Short | 533 (K) |
| Shares Short P.Month | 341 (K) |
| EPS | -4.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.6 % |
| Return on Equity (ttm) | -78.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|